Legend Biotech's IPO Blows Past Expectations

Legend Biotech's IPO Blows Past Expectations

On Friday, Legend Biotech (NASDAQ: LEGN) became the latest biotechnology start-up to pull off a surprisingly successful initial public offering. The cell-based cancer therapy developer originally intended to raise around $350 million, but investors eager to invest in a corner of the economy relatively unaffected by the COVID-19 pandemic piled in and pushed Legend's haul up to a stunning $424 million.